On June 12, 2025, Mersana Therapeutics, Inc. held its Annual Meeting where stockholders approved proposals including the election of three directors, an advisory vote on executive pay, the selection of Ernst & Young as auditors, and a reverse stock split of their shares. Overall, the voting results were over 83 million in favor for the stock split proposal with about 2.5 million against.